By Adriano Marchese
Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update, and that it was canceling its two cancer drug trial programs.
The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies.
"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions," it said.
As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents.
The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability.
The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment that uses the body's own immune system to fight certain forms of cancer. In this case, lung cancer and melanoma.
Achilles Therapeutics said that it will consider engaging third parties who are developing alternative methods to target clonal neoantigens for the treatment of cancers.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 19, 2024 07:44 ET (11:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。